News

Duo Oncology Completes Favorable PreIND Meeting

May 17, 2022

DUO ONCOLOGY ANNOUNCES SUCCESSFUL COMPLETION OF A PRE-IND MEETING WITH THE FDA. Favorable Written Option Confirms Clear Roadmap for DUO-207 Develop as First-Line Therapy for Pancreatic Cancer and Other Solid Malignancies.

Duo Oncology Places 2nd in National Life Science Startup Symposium

Apr 15, 2022

Duo Oncology places second in Pismo Ventures’ inaugural Life Science Startup Symposium

Duo Oncology Signs Exclusive License with University of Pittsburgh

Mar 17, 2022

Duo Oncology Continues Development of Cancer Nanomedicine Platform and Products from Dr. Song Li of the Pitt Center for Pharmacogenetics

Duo Oncology Earns Orphan Designation

Feb 22, 2022

EMA Awards Lead Product DUO-207 Orphan Designation for Pancreatic Cancer

Duo Oncology Announces Key Leadership Team Addition

Jan 25, 2022

Dr. Katie Eichinger PharmD, PhD Joins Team as Director of Operations.

Duo Oncology to Hire Second Full Time Team Member

Jul 15, 2021

With manufacturing, non-clinical studies and regulatory filings all ongoing, Duo Oncology is expanding its full-time team.

Duo Oncology Announces Close of Initial Seed Investment

Feb 12, 2021

Duo Oncology is pleased to announce a $1M+ seed investment led by UPMC oncologists Dr. Stanley Marks and Dr. Jing-Zhou Hou.

Duo Oncology Joins LifeX Incubator

Nov 3, 2020

LifeX Labs welcomes new portfolio company, Duo Onoclogy, into incubator program.

Duo Oncology Appoints Dr. Stanley Marks to Board of Directors

Oct 13, 2020

Duo Oncology is pleased to welcome Dr. Stanley Marks to its board of directors. Dr. Marks is a world renown oncology and chairman of the UPMC Hillman Cancer Center.

Duo Oncology Options Nanoparticle Platform from University of Pittsburgh

Jul 22, 2020

Duo Oncology signed an option to exclusively license nanoparticle prodrug chemistry patented developed in the laboratory of Dr. Song Li and patented by the University of Pittsburgh